13F HOLDINGS REPORT
Aisling Capital Management LP
Quarter ended Q3 2025 · Filed November 12, 2025 · Accession 0001766721-25-000006
Total Value
$456.4M
Positions
14
Other Managers
0
Confidential Omitted
No
Holdings (14)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | BridgeBio Pharma Inc. (BBIO) | BBIO | 6,089,611 | $316.3M | 69.29% |
| 2 | Verona Pharma plc (VRNA) | 925050106 | 615,352 | $65.7M | 14.39% |
| 3 | Syndax Pharmaceuticals, Inc. (SNDX) | SNDX | 1,316,806 | $20.3M | 4.44% |
| 4 | Nuvation Bio Inc. (NUVB) | NUVB | 2,960,659 | $11.0M | 2.40% |
| 5 | Monte Rosa Therapeutics Inc (GLUE) | GLUE | 1,472,331 | $10.9M | 2.39% |
| 6 | Bicara Therapeutics Inc. (BCAX) | BCAX | 568,919 | $9.0M | 1.97% |
| 7 | Compass Pathways Plc (CMPS) | CMPS | 1,198,418 | $6.9M | 1.50% |
| 8 | BridgeBio Oncology Therapeutics (BBOT) | BBOT | 564,625 | $6.5M | 1.43% |
| 9 | Biomea Fusion Inc (BMEA) | BMEA | 2,048,757 | $4.1M | 0.91% |
| 10 | Scholar Rock Holding Corporation (SRRK) | SRRK | 77,031 | $2.9M | 0.63% |
| 11 | CalciMedica, Inc. (CALC) | CALC | 521,114 | $1.6M | 0.35% |
| 12 | Aclaris Therapeutics Inc (ACRS) | ACRS | 434,455 | $825,465 | 0.18% |
| 13 | Marker Therapeutics, Inc. (MRKR) | MRKR | 325,370 | $290,425 | 0.06% |
| 14 | OnKure Therapeutics, Inc. (OKUR) | OKUR | 88,607 | $243,669 | 0.05% |